Patents by Inventor Robert McKay

Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090306005
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 10, 2009
    Applicant: Isis Phamaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
  • Publication number: 20090292006
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: November 26, 2009
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20090258931
    Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.
    Type: Application
    Filed: February 19, 2009
    Publication date: October 15, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
  • Publication number: 20090221671
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.
    Type: Application
    Filed: May 24, 2006
    Publication date: September 3, 2009
    Inventors: Sanjay Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
  • Publication number: 20090200902
    Abstract: A portable workstation includes wheels, a tabletop, a generally planar member and a chassis joining the wheels, the tabletop and the planar member. While joined to the wheels and the tabletop by the chassis, the planar member is movable between a protracted position and a retracted position. A majority of the planar member extends above the tabletop in the protracted position, and a majority of the planar member does not extend above the tabletop in the retracted position.
    Type: Application
    Filed: April 24, 2009
    Publication date: August 13, 2009
    Applicant: BRADYQUIN, LLC
    Inventors: Jodi McKay, Ian D. Kovacevich, Thomas James Philpott, Robert McKay, Brett Rhinehardt, Daniel Lee Bizzell
  • Patent number: 7563884
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: July 21, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Jacqueline R. Wyatt, Susan M. Freier, Brett P. Monia, Madeline M. Butler, Robert McKay
  • Publication number: 20090124009
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: March 11, 2008
    Publication date: May 14, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
  • Publication number: 20080280845
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.
    Type: Application
    Filed: May 24, 2006
    Publication date: November 13, 2008
    Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
  • Publication number: 20080197133
    Abstract: An easily removable fire sprinkler head paint cover to be temporarily installed over and around a fire sprinkler head so as to prevent paint or other finishing materials from coming into contact with a fire sprinkler head and to allow for uniform and systematic painting or finishing of walls or ceilings in which fire sprinkler heads are installed.
    Type: Application
    Filed: February 20, 2007
    Publication date: August 21, 2008
    Inventors: Donald Robert McKay, Darrell Edward Fletcher
  • Patent number: 7399853
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: July 15, 2008
    Assignee: ISIS Pharmaceuticals
    Inventors: Susan M. Freier, Kenneth W. Dobie, Sanjay Bhanot, Robert McKay
  • Publication number: 20080153767
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Application
    Filed: April 23, 2007
    Publication date: June 26, 2008
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
  • Publication number: 20080015162
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: January 17, 2008
    Inventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett Monia, Punit Seth, Andrew Siwkowski, Eric Swayze, Edward Wancewicz
  • Publication number: 20080000171
    Abstract: A portable workstation includes wheels, a tabletop, a generally planar member and a chassis joining the wheels, the tabletop and the planar member. While joined to the wheels and the tabletop by the chassis, the planar member is movable between a protracted position and a retracted position. A majority of the planar member extends above the tabletop in the protracted position, and a majority of the planar member does not extend above the tabletop in the retracted position.
    Type: Application
    Filed: June 16, 2006
    Publication date: January 3, 2008
    Applicant: BRADYQUIN, LLC
    Inventors: Jodi McKay, Robert McKay, Brett Rhinehardt, Daniel Lee Bizzell, Ian D. Kovacevich, Tom Philpott
  • Publication number: 20070275913
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Application
    Filed: April 12, 2007
    Publication date: November 29, 2007
    Inventors: Brett Monia, C. Bennett, William Gaarde, Trisha Lockhart, Robert McKay
  • Publication number: 20070238687
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 11, 2007
    Inventors: Sanjay Bhanot, Susan Freier, Kenneth Dobie, Robert McKay
  • Publication number: 20070238688
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 11, 2007
    Inventors: Sanjay Bhanot, Susan Freier, Kenneth Dobie, Robert McKay
  • Publication number: 20070238689
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 11, 2007
    Inventors: Sanjay Bhanot, Susan Freier, Kenneth Dobie, Robert McKay
  • Publication number: 20070238690
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 11, 2007
    Inventors: Sanjay Bhanot, Lynnetta Watts, Robert McKay
  • Publication number: 20070149472
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Application
    Filed: December 6, 2006
    Publication date: June 28, 2007
    Inventors: Robert McKay, Nicholas Dean
  • Patent number: D546965
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: July 17, 2007
    Assignee: McNeil-PPC, Inc.
    Inventors: Sandra Arce, Silvio J. DiMarchi, Brenda Williams-Halsey, Sheng-Fu Lee, Robert McKay, Lawrence P. Scanzillo